Literature DB >> 22119990

Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention.

Laia Alemany1, Cristina Pérez, Sara Tous, Antonio Llombart-Bosch, Belen Lloveras, Enrique Lerma, Rosa Guarch, Miguel Andújar, Adela Pelayo, Maria Alejo, Jaume Ordi, Joellen Klaustermeier, Julio Velasco, Nuria Guimerà, Omar Clavero, Xavier Castellsagué, Wim Quint, Nubia Muñoz, F Xavier Bosch, Silvia de Sanjosé.   

Abstract

OBJECTIVE: Human papillomavirus (HPV) genotype distribution in invasive cervical cancer (ICC) is critical to guide the introduction and to assess the impact of HPV prophylactic vaccines. This study aims to provide specific information for Spain.
METHODS: 1043 histological confirmed ICC cases diagnosed from 1940 to 2007 from six Spanish regions were assembled. HPV DNA detection was performed by SPF(10) broad-spectrum PCR followed by deoxyribonucleic acid enzyme immunoassay and genotyping by reverse hybridization line probe assay (LiPA(25)) (version 1).
RESULTS: Of 1043 ICC cases, 904 were HPV DNA positive (adjusted prevalence: 89.1%). The eight most common types, in decreasing order, were HPV 16, 18, 33, 31, 45, 35, 52 and 56, accounting for more than 90% of cases. HPV 16 and 18 contributed to 72.4% of all HPV positive ICC cases. In cervical adenocarcinomas, this contribution increased up to 94%. HPV 16 and 18 relative contributions showed a stable pattern over the 60 year study period. HPV 45, 18 and 16-positive ICC cases presented at younger ages than cases with other HPV types (adjusted mean age: 43.8, 45.2, 52.6 and 57.7 years, respectively).
CONCLUSIONS: HPV 16 and 18 accounted together for a 72.4% of positive cases, with no statistically significant changes in their relative contributions over the last decades. In 94% of cervical adenocarcinomas we identified at least one of the two HPV types included in the current vaccines (HPV 16/18). Results suggest a major impact of HPV vaccines on reduction of ICC burden in Spain in the HPV vaccinated cohorts.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22119990     DOI: 10.1016/j.ygyno.2011.11.024

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  RETRACTED ARTICLE: The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 6 Years After Approval.

Authors:  Elisa Martín-Merino; Ana Llorente-García; Dolores Montero Corominas; Consuelo Huerta-Álvarez
Journal:  Pharmaceut Med       Date:  2019-04

2.  The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval.

Authors:  Elisa Martín-Merino; Ana Llorente-García; Belén Castillo Cano; Dolores Montero Corominas; Consuelo Huerta-Álvarez
Journal:  Pharmaceut Med       Date:  2019-12

3.  The distribution of high-risk human papillomaviruses is different in young and old patients with cervical cancer.

Authors:  Mariano Guardado-Estrada; Eligia Juárez-Torres; Edgar Román-Bassaure; Ingrid Medina-Martinez; Ana Alfaro; Rosa Elba Benuto; Michael Dean; Nicolás Villegas-Sepulveda; Jaime Berumen
Journal:  PLoS One       Date:  2014-10-08       Impact factor: 3.240

4.  Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study.

Authors:  Katsiaryna Holl; Andrzej M Nowakowski; Ned Powell; W Glenn McCluggage; Edyta C Pirog; Sabrina Collas De Souza; Wiebren A Tjalma; Mats Rosenlund; Alison Fiander; Maria Castro Sánchez; Vasileia Damaskou; Elmar A Joura; Benny Kirschner; Robert Koiss; John O'Leary; Wim Quint; Olaf Reich; Aureli Torné; Michael Wells; Lukas Rob; Larisa Kolomiets; Anco Molijn; Alevtina Savicheva; Elena Shipitsyna; Dominique Rosillon; David Jenkins
Journal:  Int J Cancer       Date:  2015-07-14       Impact factor: 7.396

5.  Reduction in the burden of hospital admissions due to cervical disease from 2003-2014 in Spain.

Authors:  Noelia López; Ángel Gil-de-Miguel; Raquel Pascual-García; Ruth Gil-Prieto
Journal:  Hum Vaccin Immunother       Date:  2017-12-21       Impact factor: 3.452

Review 6.  HPV-Negative Cervical Cancer: A Narrative Review.

Authors:  Francesca Arezzo; Gennaro Cormio; Vera Loizzi; Gerardo Cazzato; Viviana Cataldo; Claudio Lombardi; Giuseppe Ingravallo; Leonardo Resta; Ettore Cicinelli
Journal:  Diagnostics (Basel)       Date:  2021-05-26

7.  Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction.

Authors:  Claudia Hopenhayn; Amy Christian; Warren Jay Christian; Meg Watson; Elizabeth R Unger; Charles F Lynch; Edward S Peters; Edward J Wilkinson; Youjie Huang; Glenn Copeland; Wendy Cozen; Maria Sibug Saber; Marc T Goodman; Brenda Y Hernandez; Martin Steinau; Christopher Lyu; Thomas T Tucker; Mona Saraiya
Journal:  J Low Genit Tract Dis       Date:  2014-04       Impact factor: 3.842

8.  Cross-sectional study about primary health care professionals views on the inclusion of the vaccine against human papillomavirus in the vaccine schedules.

Authors:  M Reyes Oliver Pérez; Victoria Bravo Violeta; Ana Vazquez Del Campo; Cristina Ruiz; Sonia Yáñez Castaño; Laura P Pérez Conde; Jesús S Jiménez López
Journal:  Infect Agent Cancer       Date:  2015-11-16       Impact factor: 2.965

9.  Uncommon and rare human papillomavirus genotypes relating to cervical carcinomas.

Authors:  Na Rae Kim; Myunghee Kang; Soon Pyo Lee; Hyunchul Kim; Jungsuk An; Dong Hae Chung; Seung Yeon Ha; Hyun Yee Cho
Journal:  Korean J Pathol       Date:  2014-02-25

10.  Epidemiologic and economic burden of HPV diseases in Spain: implication of additional 5 types from the 9-valent vaccine.

Authors:  Noelia López; Aureli Torné; Agustín Franco; María San-Martin; Elisabet Viayna; Carmen Barrull; Nuria Perulero
Journal:  Infect Agent Cancer       Date:  2018-05-02       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.